{"id":"NCT02304484","sponsor":"Amgen","briefTitle":"Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab","officialTitle":"A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11-24","primaryCompletion":"2018-03-09","completion":"2018-03-09","firstPosted":"2014-12-02","resultsPosted":"2019-03-19","lastUpdate":"2019-03-19"},"enrollment":770,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["AMG 145","Repatha"]}],"arms":[{"label":"Evolocumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From first dose of evolocumab up to 30 days after the last dose, or end of study, whichever was earlier, up to 108 weeks.","effectByArm":[{"arm":"Evolocumab","deltaMin":526,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":126,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Greece","Hungary","Iceland","Ireland","Israel","Italy","Malaysia","Mexico","Netherlands","Norway","Poland","Russia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":153,"n":770},"commonTop":["Hypertension"]}}